← Back to News

Treatment for COVID-19 Ready for Clinical Trials Phase 2b

Wed Oct 06 2021

Our treatment aims to prevent the dangerous overreaction of the immune system that results in patients becoming critically ill due to COVID-19. Using Biobank data, we identified CDK6 as a drug target. Inhibiting it will lower neutrophil cell count, which, when too high, is strongly linked with the severe and critical course of COVID-19. This potential treatment has been endorsed by Key Opinion Leaders from Harvard Medical School, Germany’s Robert-Koch-Institute and the University of Marburg. We are preparing a clinical phase 2b trial to show efficacy.